A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
=== Political office === The Law of June 6, 2000, requires gender parity on candidate lists for municipal, regional, senatorial, and European elections. In legislative elections, parties that do not adhere to parity are subject to financial penalties. In 2012, women represented 26.9% of the French National Assembly and 36.4% of the European Parliament. In 2017, 223 women were elected to the National Assembly, constituting 38.65% of its members. Globally, no national parliament has a female majority in both chambers. Rwanda and Bolivia have female majorities in their lower houses, though their upper houses have male majorities.
The highest approval rating for the government was in the Northeast (65%), among people with up to a completed elementary education (60%), those earning two minimum wages (59%), and among women (59%). In a survey conducted by PoderData between 24 and 26 September with 2,500 people, a margin of error of 2 percentage points, and a confidence level of 95%, the government obtained 48% approval and 45% disapproval. The regions that most approve of the Lula government are the Southeast and the Northeast, and his government is more approved among younger and older poor and middle-class women. Lula as a person received 36% of mentions as excellent or good, 25% as regular, and 35% as bad or terrible. The survey also asked whether respondents liked Lula's administration more than Bolsonaro's. Forty-eight percent agreed with the statement, 40% disagreed, and 9% said there was no difference. Among evangelicals, government approval fell by two percentage points to 32%, and rejection rose to 64%. Among Catholics, approval fell by 3 percentage points to 57%, and disapproval rose to 36%. In a survey released by Paraná Pesquisas on 13 January 2025, it was revealed that the negative evaluation of President Luiz Inácio Lula da Silva's government exceeded the positive one. According to the survey data, 11.1% of Brazilians considered the government excellent and 22.7% classified it as good, totaling 33.8% positive evaluation. On the other hand, 42.6% of respondents evaluated the government as bad (8.4%) or terrible (34.2%).
==== Other drugs ==== Acamprosate (Alcomed; Aotal; calcium acetylhomotaurinate; Campral; Campral EC; NS-11; Regtect; Sobriol; Zulex) – various actions – alcoholism Baclofen (Baclocur) – GABAB receptor agonist – alcoholism Calcium carbimide (Temposil) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism Cyanamide – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism Disulfiram (Antabuse, Antabus) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism Flumazenil (flumazepil; Anexate) – GABAA receptor negative allosteric modulator/benzodiazepine antidote – benzodiazepine overdose Lofexidine (BA-168; BritLofex; Lucemyra; MDL-14042; MDL-14042A; RMI-14042A) – α2-adrenergic receptor agonist – opioid-related disorders Sodium oxybate (Alcover; SMO immediate release formulation) – GABAB and GHB receptor agonist – alcoholism
Sources: en.wikipedia.org
=== 3. Clinical Examples: CAL vs Pseudopocket vs Gingival Enlargement === Patients with clinical attachment loss typically present with features of chronic periodontitis. A common example is a middle-aged adult with deep true periodontal pockets, gingival recession, tooth mobility, furcation involvement, and radiographic evidence of alveolar bone loss. Another example includes localized attachment loss due to aggressive toothbrushing, presenting as cervical recession with exposed CEJ and true pocket formation. Key identifying features include irreversible attachment loss, apical migration of the JE, and true periodontal pocket formation. Pseudopockets are commonly seen in younger patients with plaque-induced gingivitis. For example, a teenager may present with swollen, edematous gingiva, probing depths of 6–10 mm, a hidden CEJ, and no radiographic bone loss. Similarly, patients with orthodontic brackets may develop localized gingival swelling around brackets, resulting in 5–7 mm probing depths without attachment loss. These cases are characterized by false pockets, increased probing depth due solely to gingival swelling, and reversibility with proper plaque control. Gingival enlargement presents differently depending on etiology. Drug-induced cases, such as in patients taking phenytoin or nifedipine, show bulbous, firm, bead-like gingiva with buried CEJs and minimal bleeding on probing. Hormonal enlargement, such as pregnancy epulis, appears as localized, red, soft, and friable gingival masses with partially hidden CEJs and increased sulcus depth.
The pressure a liquid exerts against the sides and bottom of a container depends on the density and the depth of the liquid. If atmospheric pressure is neglected, liquid pressure against the bottom is twice as great at twice the depth; at three times the depth, the liquid pressure is threefold; etc. Or, if the liquid is two or three times as dense, the liquid pressure is correspondingly two or three times as great for any given depth. Liquids are practically incompressible – that is, their volume can hardly be changed by pressure (water volume decreases by only 50 millionths of its original volume for each atmospheric increase in pressure). Thus, except for small changes produced by temperature, the density of a particular liquid is practically the same at all depths. Atmospheric pressure pressing on the surface of a liquid must be taken into account when trying to discover the total pressure acting on a liquid. The total pressure of a liquid, then, is ρgh plus the pressure of the atmosphere. When this distinction is important, the term total pressure is used. Otherwise, discussions of liquid pressure refer to pressure without regard to the normally ever-present atmospheric pressure. The pressure does not depend on the amount of liquid present. Volume is not the important factor – depth is. The average water pressure acting against a dam depends on the average depth of the water and not on the volume of water held back. For example, a wide but shallow lake with a depth of 3 m (10 ft) exerts only half the average pressure that a small 6 m (20 ft) deep pond does.
Steiner (1945), scholar of social policy and fourth president of the Brookings Institution Richard Heffner (1946), professor and host of The Open Mind Fritz Stern (1946), Seth Low Professor of History Emeritus; pre-eminent in German studies George Herbert Borts (1947), economist at Brown University and managing editor of The American Economic Review 1969–1980 William Bell Dinsmoor Jr. (1947), Classical archaeologist and architectural historian John Michael Montias (1947), economist and art historian at Yale University Harold E. Pagliaro (1947), professor of English literature at Swarthmore College Howard Stein (1947), philosopher at the University of Chicago Lambros Comitas (1948), anthropologist Elihu Katz (1948), sociologist and communication scholar, known for developing the two-step flow of communication theory Norman Kelvin (1948), literary scholar, professor at City College of New York and Graduate Center, CUNY Victorino Tejera (1948), professor of philosophy and comparative literature at Stony Brook University Uriel Weinreich (1948), linguist and professor at Columbia University Albert Elsen (1949), professor at Stanford University and Auguste Rodin expert Donald M. Friedman (1949), professor of Renaissance literature at University of California, Berkeley Marvin Harris (1949), anthropologist famous for developing cultural materialism Anthony Leeds (1949), anthropologist, professor at Boston University Robert F.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.